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Eukaryotic initiation factor 2B (eIF2B) serves as 
a vital control point within protein synthesis and 
regulates translation initiation in response to 
cellular stress. Mutations within eIF2B result in 
the fatal disease, leukoencephalopathy with 
vanishing white matter (VWM). Previous 
biochemical studies on VWM mutations have 
illustrated that changes in the activity of eIF2B 
poorly correlates with disease severity. This 
suggests that there may be additional 
characteristics of eIF2B contributing to VWM 
pathogenesis. Here, we investigated whether the 
localisation of eIF2B to eIF2B bodies was 
integral for function and whether this localisation 
could provide insight into the pathogenesis of 
VWM. We demonstrate that the regulatory 
subunit, eIF2Bα, is required for the assembly of 
eIF2B bodies in yeast and that loss of eIF2B 
bodies correlates with an inability of cells to 
regulate eIF2B activity.  Mutational analysis of 
eIF2Bα showed that missense mutations which 
disrupt the regulation of eIF2B similarly disrupt 
the assembly of eIF2B bodies. In contrast, when 
eIF2Bα mutations which impact the catalytic 
activity of eIF2B were analysed, eIF2B bodies 
were absent and instead eIF2B localised to small 
foci, termed microfoci. FRAP analysis 
highlighted that within these microfoci, eIF2 
shuttles more slowly indicating that formation of 
eIF2B bodies correlates with full eIF2B activity. 
When eIF2Bα VWM mutations were analysed a 
diverse impact on localisation was observed, 
which did not seem to correlate with eIF2B 
activity.  These findings provide key insights into 
how the eIF2B body assembles and suggest that 
the body is a fundamental part of the translational 
regulation via eIF2α phosphorylation. 
 
INTRODUCTION 
Eukaryotic genomes encode many thousands of 
proteins and through the process of protein 
synthesis from mRNA or translation, the cell can 
rapidly control its gene expression profile to 
promote cellular homeostasis. The initiation step 
of translation is rate limiting and therefore 
provides a critical control point in gene 
expression. The highly conserved heterotrimeric 
G-protein, eukaryotic initiation factor 2 (eIF2), is 
essential for the initiation and regulation of 
translation. In its active GTP bound form, eIF2 
binds to a methionyl initiator transfer RNA (Met-
tRNAi) molecule to form a ternary complex (TC) 
(1). Facilitated by a number of eIFs, the TC is 
loaded onto the 40S ribosomal subunit and is 
recruited to a target mRNA molecule, allowing 
for subsequent ribosomal scanning and start 
codon recognition (1). Upon start codon 
recognition, eIF2-GTP is hydrolysed by the 
GTPase-activating protein, eIF5 (2) and is 
released from the ribosome in its inactive GDP 
bound form, in complex with eIF5 (1). For 
subsequent rounds of translation to occur within 
the cell, active eIF2-GTP must be replenished. 
eIF2 has a higher affinity for GDP than GTP (3) 
and therefore the multisubunit protein eIF2B is 
required to catalyse this guanine nucleotide 
exchange (4). In yeast, eIF5 functions as a GDP 
dissociation inhibitor (GDI), preventing any 
spontaneous recycling of GDP to GTP on eIF2 
(5). In addition to its role as a guanine nucleotide 
exchange factor (GEF), in yeast eIF2B also acts 
as a GDI displacement factor (GDF), releasing 
eIF2-GDP from eIF5 (6).  
 
Although functionally similar to other guanine 
nucleotide exchange factors of the ras 
superfamily, eIF2B has a much more complex 
quaternary structure. It is composed of five 
nonidentical subunits termed, α, β, δ, γ and ε, 
encoded in yeast by the genes: GCN3, GCD7, 
GCD2, GCD1 and GCD6, respectively. The 
native form of eIF2B is composed of a dimer of 
heteropentamers and so is decameric (7, 8). 
eIF2Bγ-eIF2Bε heterodimers reside on both 
flanks of the structure and are responsible for the 
protein’s GEF activity (4). Heterodimers of 
eIF2Bβ and δ subunits bind eIF2Bγε 
heterodimers and reside in the core of the 
decameric arrangement, stabilised in this 
conformation by an eIF2Bα homodimer. 
Structural analysis of both yeast and mammalian 
eIF2B has provided models for how the 
decameric structure is formed and how eIF2 can 
interact with the decamer (9-13). In mammalian 
cells, Wortham et al. identified that all eIF2B 
subunits, except eIF2Bα, are stoichiometrically 
regulated (14). Stable expression of eIF2Bε relies 
on similar levels of γ to be co-expressed; 
correspondingly eIF2Bδ requires similar levels of 
eIF2Bεγ and β. Any surplus protein subunits are 
degraded by the ubiquitin-proteasome system. 
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This study indicated that the eIF2B holocomplex 
may be built around the eIF2Bεγβδ subcomplex, 
with eIF2Bα2 homodimers bridging two tetramers 
to complete the decameric holocomplex. In line 
with this model, Tsai et al., demonstrated that in 
the absence of eIF2Bα, eIF2B exists as an 
eIF2Bεγβδ tetramer (15).  
 
The subunit complexity of eIF2B lends itself as a 
target of tight regulation. As the process of 
translation involves a significant amount of 
cellular energy, tight regulation is crucial in 
response to adverse cellular conditions. One of 
the best studied and most diverse mechanisms of 
translational control in response to cellular stress 
is the integrated stress response (ISR), known as 
the general amino acid control (GAAC) pathway 
in yeast (16, 17). The ISR involves a series of 
cellular stress sensing pathways that regulate 
translation through the common mechanism of 
eIF2 phosphorylation (18). In mammalian cells, 
four eIF2α kinases exist, whereas in yeast a single 
kinase, Gcn2p (general control nonderepressible 
2), is responsible for the phosphorylation of 
eIF2α at serine 51 in response to amino acid 
starvation (19). Phosphorylation of eIF2 at this 
site converts eIF2 from a substrate to an inhibitor 
of eIF2B GEF activity. While the α, β and δ 
subunits of eIF2B are dispensable for GEF 
activity, they are responsible for tight regulation 
of this activity by phosphorylated eIF2 (20, 21). 
The inhibition of eIF2B GEF activity induces 
global translational repression within the cell. 
Paradoxically, a number of stress-responsive 
proteins are translationally upregulated to favour 
homeostatic reprogramming (18). The translation 
of these proteins is most commonly controlled by 
the presence of upstream open reading frames 
(uORFs) in the 5’UTR of the mRNAs, first 
demonstrated in yeast for GCN4 mRNA (22).  
 
Recent structural studies in both yeast and 
mammalian systems have solved structures of 
eIF2B bound to both phosphorylated and non-
phosphorylated eIF2α, (9-13, 23). Interestingly, 
although the structure of eIF2B is highly 
conserved across species (9, 10, 13), 
phosphorylated eIF2α appears to interact and 
inhibit eIF2B via distinct mechanisms within 
yeast and mammalian cells. While in mammalian 
cells, phosphorylated and non-phosphorylated 
eIF2α bind to different regions of eIF2B, in yeast, 
they share a binding pocket (10). eIF2α binds to 
the eIF2B regulatory subunits and this binding 
position is favourable for nucleotide exchange. 
Upon phosphorylation of eIF2α, conformational 
changes in its structure are believed to enhance 
the binding of eIF2α to eIF2Bα and δ subunits. It 
is this conformational change in eIF2B that 
displaces the catalytic domain of eIF2Bε, 
responsible for carrying out nucleotide exchange, 
from its original close proximity to eIF2 thus 
inhibiting nucleotide exchange (10).  
 
Localisation studies in both yeast and mammalian 
systems have shown that eIF2B accumulates at 
specific foci within the cytoplasm of the cell (24-
31). These foci have been termed eIF2B bodies 
and in yeast appear as one large cytoplasmic 
granule that morphologically exists as a 
filamentous-like structure. eIF2 also localises to 
eIF2B bodies raising the possibility that eIF2B 
bodies are sites where eIF2B GEF activity occurs 
and is regulated within the cell. In 2005, 
Campbell et al., demonstrated that in S. 
cerevisiae eIF2B is a stable component of eIF2B 
bodies, whereas the association of eIF2 is 
dynamic, with eIF2 transiting through the eIF2B 
body at a rate that correlates to the cellular level 
of eIF2B GEF activity (24). In 2010, Taylor et al 
observed that eIF2B bodies were motile 
throughout the cytoplasm (26).  This movement 
is important for effective translation initiation as 
butanol treatment hinders eIF2B body movement 
and this lack of movement correlates with the 
inhibition of translation initiation. These data 
provide evidence to suggest eIF2B bodies are 
sites of eIF2B GEF activity and regulation, 
however recent interest in eIF2B bodies has 
provided some conflicting interpretations. One 
study has suggested that eIF2B bodies are not 
present in S. cerevisiae under steady-state 
growth, but only form under glucose limiting 
conditions (28). Interestingly, another study 
highlighted that eIF2B bodies were not induced 
during acute glucose starvation but were formed 
upon energy depletion (during stationary phase) 
as a mechanism for sequestering eIF2B proteins 
to inhibit their function (30, 31). Therefore, the 
significance of eIF2B assembly into eIF2B 





The importance of understanding eIF2B 
localisation is heightened by the fact that in 
mammalian cells, mutations within eIF2B result 
in the fatal, autosomal recessive disease, 
leukoencephalopathy with vanishing white 
matter (VWM) (32). To date, over 200 VWM 
mutants have been identified spanning all five 
subunits (33). The relationship between mutant 
eIF2B function and disease severity remains 
poor. VWM causing mutations have been 
identified that affect neither decameric complex 
formation nor eIF2B activity in vitro but cause 
some of the most severe forms of VWM in vivo 
(34, 35). Understanding eIF2B body formation 
and regulation could uncover common 
pathophysiological mechanisms across the broad 
spectrum of causative mutations. Although 
GCN3, which encodes eIF2Bα, is the only 
nonessential eIF2B gene in yeast, it is still critical 
for stabilising eIF2B in its decameric 
conformation and for the regulation of eIF2B 
activity during cellular stress. Here we 
investigate the importance of eIF2Bα to eIF2B 
body assembly and activity. Using S. cerevisiae, 
we show that eIF2Bα (Gcn3p in S. cerevisiae) is 
central to the formation of eIF2B bodies and 
suggest that eIF2B bodies are a fundamental part 
of the translational regulation via eIF2α 
phosphorylation. Additionally, VWM causative 
mutations disrupt eIF2B body formation and 
regulation, providing the first evidence that 





eIF2B localisation varies between different 
yeast strains 
Using C-terminally yeGFP tagged eIF2B 
subunits we have previously shown that, during 
steady state growth, all five subunits of eIF2B co-
localise to eIF2B bodies (24-27). Recently, a 
number of groups have presented conflicting data 
about whether these eIF2B bodies exist during 
steady state growth or only form under specific 
starvation conditions (28, 30, 31). A potential 
explanation for these conflicting results is that 
different GFP tags may be influencing the 
aggregation of eIF2B. In order to investigate this, 
we first observed eIF2B body formation by 
individually tagging each eIF2B subunit with 
GFP and determining the percentage of cells in 
which eIF2B bodies were present. We 
hypothesized that if the eIF2B bodies that we 
have observed during steady state growth were 
due to aggregation of the GFP tag, we would 
expect to observe a similar percentage of cells 
containing eIF2B bodies for all 5 GFP tagged 
eIF2B subunits. While a similar percentage of 
cells contained eIF2B bodies when the eIF2Bγ 
(48 %), ε (51 %) and β (56 %) subunits were 
tagged, a lower percentage of cells contained 
eIF2B bodies when eIF2Bα (20 %) or δ (30 %) 
subunits where tagged (Figure 1A). These results 
suggest that it is unlikely that the GFP tag we 
have used is responsible for eIF2B body 
formation, rather, the ability of eIF2B to form 
bodies is influenced by the subunit that is tagged. 
Another possible explanation for differences in 
eIF2B body formation is variation between yeast 
strains, which are known to have differing 
responses to environmental stresses (36). In our 
previous studies, we have utilised S. cerevisiae 
W303-1A strain, while others have characterised 
eIF2B bodies in the BY4741 strain. To determine 
whether various lab strains localise eIF2B 
differently, the eIF2Bγ subunit was C-terminally 
GFP-tagged in the auxotrophic W303-1A, 
BY4741 and S288c background strains and 
eIF2B localisation was assessed. There was no 
difference in growth between strains (Fig S1). 
During steady state growth, a similar number of 
cells showing eIF2B bodies was observed for the 
W303-1A and S288c backgrounds (52 % and 50 
% respectively), while a significantly lower 
number of cells were observed to show eIF2B 
bodies in the BY4741 strain background (11 %).   
To determine whether there was any change in 
the localisation upon stress, the cells were 
subjected to acute glucose starvation (30 min) 
and amino acid starvation (15 min). Previously, 
we had observed that the level of fluorescence 
within eIF2B bodies increased upon amino acid 
starvation and that this was dependent on the 
phosphorylation of eIF2α (24). Interestingly, 
upon amino acid starvation an increase in the 
number of cells showing eIF2B bodies was 
observed for all strains (Figure 1B).  Whilst for 
the W303-1A and the S288c strains this increased 
percentage resulted in a 1.2-fold increase of cells 
with eIF2B bodies, for the BY4741 strain this 
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increased percentage of cells represents a much 
greater 2.3 fold increase. In contrast to these 
increases, following glucose starvation, the 
number of cells displaying eIF2B bodies slightly 
decreased for all strains W303-1A, eIF2Bγ-GFP 
(46%), S288c, eIF2Bγ-GFP (37%) and BY4741 
eIF2Bγ-GFP (6%) however compared to SCD 
these differences were not found to be 
statistically significant. These results are 
consistent with data showing that eIF2B is not 
directly involved in translational control 
following glucose starvation (37-39). Overall, 
these results suggest that under normal growth, 
the level of eIF2B localisation to bodies depends 
on the S. cerevisiae strain, but that the trends in 
terms of responses to nutritional stress are similar 
and are dependent on stresses which target eIF2B 
activity.  
 
Deletion of eIF2Bα disperses eIF2B bodies 
In our previous studies we have shown that 
strains harbouring gcn3 point mutations show no 
eIF2B bodies (26). eIF2Bα (Gcn3p in yeast) is 
essential for decameric formation and therefore 
this phenotype could reflect destabilisation of the 
decameric complex. eIF2Bα is dispensable for 
eIF2B GEF activity but is required to regulate this 
activity in response to cellular stress. Within the 
eIF2B decameric complex, the eIF2Bα 
homodimer forms part of the regulatory core, 
which after cellular stress forms a high affinity 
interaction with phosphorylated eIF2 to prevent 
GDP to GTP exchange on non-phosphorylated 
eIF2 within the cell (23). Strains deleted for the 
eIF2Bα gene are viable in yeast under steady state 
conditions, however they cannot survive ISR 
activating stress conditions (18). To test whether 
eIF2B bodies form when it is no longer possible 
to stabilise the decameric complex, eIF2Bα 
(Gcn3p in yeast) was deleted in strains 
harbouring either C-terminally GFP tagged 
eIF2Bγ (Gcd1p in yeast) or eIF2α (Sui2p in 
yeast).   Upon deletion of the eIF2Bα gene, eIF2B 
does not localise to eIF2B bodies and instead is 
found completely dispersed throughout the 
cytoplasm as visualised using either eIF2Bγ-GFP 
and eIF2α-GFP strains (Figure 2A). The lack of 
response to conditions causing eIF2α 
phosphorylation in the gcn3 null strain was also 
confirmed via polysome profiling (Figure S2A).  
Localisation of eIF2B to eIF2B bodies was 
rescued when eIF2Bα (Gcn3p) was exogenously 
expressed on either a low copy centromeric or a 
high copy 2 micron plasmid (Figure 2A and 
Figure S2). Interestingly, a slight decrease in the 
number of cells showing eIF2B bodies was 
observed when eIF2Bα was over-expressed (50 
% ± 9.0% versus 37 % ± 1.2%) (Fig 2B). 
Intriguingly, in addition to eIF2B bodies, for all 
strains except the gcn3 null strain, eIF2B also 
localised to multiple smaller, punctate foci, which 
we termed microfoci however during steady state 
growth such microfoci were a rarely observed 
(Figure 2B). 
 
These results show that eIF2Bα is required for the 
localisation of eIF2B to eIF2B bodies and are 
suggestive that the complete decameric complex 
may be required for eIF2B body assembly.   
 
Mutations in eIF2Bα alter the localisation of 
eIF2B 
To further investigate the role of eIF2Bα in the 
localisation of eIF2B and to determine whether 
eIF2B bodies have a functional role in regulating 
eIF2B activity, a series of well-characterised 
Gcn3p mutants were examined (Figure 3) (40). 
These mutations confer two distinct phenotypes 
that affect either the regulatory (Gcn-) or catalytic 
(Gcd-) activity of eIF2B. Gcn- mutations prevent 
eIF2B activity from responding to cellular stress 
by impeding eIF2B-eIF2α-P interactions 
therefore allowing cells to continue eIF2B 
exchange activity even in the presence of 
phosphorylated eIF2ɑ (Figure S3A). Gcd- 
mutations reduce eIF2B GEF activity, which 
constitutively induces the expression of the stress 
responsive transcription factor Gcn4p (Figure 
S3B).  
 
Eight Gcn- and seven Gcd- Gcn3p mutants were 
analysed for their impact on eIF2B body 
formation.  The position of these mutations 
within the structure of Gcn3p can be seen in 
Figure 3. For all mutants analysed, eIF2B body 
formation was affected (Figure 4A). 
Interestingly, for the regulatory mutants (Gcn-), 
no eIF2B bodies were observed, with the 
exception of the Gcn3 (S293R) mutant, where a 
small proportion of cells showed eIF2B bodies 
(6.7%) (Figure 4Ai and B). This loss of eIF2B 
bodies was not due to a decrease in protein 
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expression (Figure S2B). This dispersal of the 
eIF2B body localisation observed in the Gcn3p 
regulatory mutants resembles the dispersal of 
eIF2B bodies in the gcn3 null strain and therefore 
seems likely to reflect the inability of these 
mutants to regulate eIF2B GEF activity rather 
than any change in subunit levels (Figure 2A).  
 
While the regulatory mutants dispersed the 
localisation of eIF2B completely, the catalytic 
mutants resulted in the localisation of eIF2B to 
multiple smaller, punctate foci, termed microfoci 
(Figure 4Aii). These mutants also resulted in 
moderate reductions of subunit expression 
(Figure S2B). The only exception within this 
group of catalytic mutations was the AA 
303//305Δ mutant where similar numbers of cells 
either dispersed eIF2B (33.5 %), formed 
microfoci (38.3 %) or formed eIF2B bodies (28.2 
%) (Figure 4B).  
 
FRAP analysis identifies slower exchange 
within the microfoci 
Using, fluorescence recovery after 
photobleaching (FRAP) analysis we have 
previously demonstrated  that the GEF activity of 
eIF2B is controlled and regulated in eIF2B 
bodies, as the rate of shuttling of eIF2 through 
eIF2B bodies was perturbed when 
phosphorylated eIF2ɑ was present  (24, 26). 
Since the eIF2Bα catalytic mutants display a 
Gcd- phenotype as assessed by their increased 
Gcn4p levels during steady state (Figure S3B), 
we postulated that disruption of the large eIF2B 
body to give microfoci (Figure 4Aii) may 
decrease the shuttling of eIF2 through eIF2B. To 
test this hypothesis, FRAP analysis was carried 
out on the AA25, 26VV, E199K and AA 
303//305Δ mutant strains. As the mutant AA 
303//305Δ also formed eIF2B bodies as well as 
microfoci, this catalytic mutant represented a 
unique opportunity to investigate differences in 
the shuttling of eIF2 between the two types of 
eIF2B localisation in a single cell.  
 
Fluorescence recovery of eIF2ɑ-GFP was 
measured over time and mean recovery curves are 
shown in Figure 5B.  Representative images 
across the different stages of the FRAP 
experiment are shown in Figure S4. Although the 
percentage of mobile eIF2 did not deviate 
significantly between the wild-type and any of 
the catalytic mutants (Figure 5Ci), the rate of eIF2 
recovery into eIF2B bodies after photobleaching 
was consistently slower in the catalytic mutants 
than in wild-type cells (Figure 5Ciii).  This is 
consistent with our previous analysis, where we 
showed a similar decreased rate of eIF2 shuttling 
for catalytic mutants in eIF2Bε (24). Consistent 
with this decreased rate, the AA25,26VV and 
E199K mutants exhibited increased half-time for 
eIF2 recovery in comparison to plasmid-borne 
wild-type GCN3 control (Figure 5Cii). 
Intriguingly, eIF2 shuttling through eIF2B bodies 
within the AA 303//305Δ mutant was comparable 
to wild-type while, eIF2 shuttling through 
microfoci within this same mutant declined 
similarly to the other microfoci forming mutants 
AA25,25VV and E199K (Figure 5). Therefore, 
FRAP analyses of eIF2 suggest that the formation 
of eIF2B bodies enhances the eIF2 shuttling 
capacity relative to eIF2B microfoci.  
 
VWM mutations in the α subunit of eIF2B 
result in altered eIF2B localisation 
Mutations within eIF2B result in the fatal disease 
leukoencephalopathy with vanishing white 
matter (VWM). Previous biochemical studies on 
VWM mutations have relied upon in vitro 
analysis of eIF2B activity, complex integrity, and 
protein stability (33). 
 
While these analyses have illustrated that VWM 
mutations can impact the activity of eIF2B, the 
scale of observed effects correlates poorly with 
disease severity (34). Given the results from our 
localisation studies for mutations that 
differentially impact the regulatory or catalytic 
activity of eIF2B, it is possible that VWM 
mutations may also affect the integrity and GEF 
activity of eIF2B bodies; providing mechanistic 
insights into VWM pathophysiology. VWM 
causative mutations have been characterised in all 
5 subunits of eIF2B, with 8 mutations identified 
in eIF2Bα (32, 33, 41, 42).  
 
Of the 8 mutations identified in eIF2Bɑ, 1 results 
in a frameshift, 1 results in a deletion and 6 are 
missense mutations.  Of the six missense mutated 
residues, only one is not conserved in yeast, 
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P278R (Q277 in yeast). Therefore, five VWM 
missense mutations K111E, N209Y, V184D, 
F240V and Y274C were investigated (Figure 6). 
While these mutations cause a range of disease 
severities in humans, no change in yeast cell 
growth was observed (Fig S5A). To determine 
what impact the VWM mutants had on the control 
of translation initiation, exponential cultures of 
the various strains were subjected to amino acid 
starvation and polysome profiling was performed 
(Figure 7A).  In line with previous work, N209Y 
was identified as a Gcn- mutation and was unable 
to respond to stress (43). While the VWM 
mutation F240V displayed a similar phenotype to 
N209Y, the remaining mutants, V184D, K111E 
and Y274C, were all able to respond to amino 
acid starvation in a similar manner to the control 
strain (Figure 7A). We next determined whether 
these VWM eIF2Bα mutations had any impact on 
the localisation of eIF2B to eIF2B bodies. We 
hypothesised that if the mutations N209Y and 
F240V had Gcn- phenotypes that caused a 
disruption to the regulatory role of Gcn3p then 
eIF2B bodies would be dispersed throughout the 
cytoplasm.  This was the case when eIF2B 
localisation was observed in the presence of the 
eIF2Bα N209Y mutation, (Figure 7B). In 
contrast, for the eIF2Bα F240V mutant strain, 
which displayed a Gcn- phenotype and could not 
respond to amino acid starvation, eIF2B bodies 
were partially disrupted with a decreased 
percentage of cells displaying them (13 %), 
(Figure 7B). The three mutations which do not 
affect the regulatory function of eIF2Bα, either 
decreased the number of cells displaying eIF2B 
bodies (K111E (29 %) and Y274C (20 %)) or in 
the case of the V184D mutant formed microfoci 
(Figure 7B). Surprisingly, these mutations did not 
show decreased eIF2B activity as measured by 
induced Gcn4 expression (Figure S5B).  
 
We next made use of our FRAP assay to 
determine if these mutants impacted upon the 
ability of eIF2α to shuttle through eIF2B bodies. 
Intriguingly, although eIF2B bodies were present 
within the mutants V184D and F240V, eIF2α-
GFP did not localise to discrete cytoplasmic 
bodies in these mutants and instead was dispersed 
throughout the cytoplasm (Figure S5D). 
Therefore, an analysis of eIF2 shuttling was not 
possible in these mutants and the lack of 
colocalization of eIF2 and eIF2B may reflect 
differences in affinities of these complexes.  
 
In contrast, for the K111E and Y274C mutants, 
eIF2α-GFP did localise to eIF2B bodies and so, 
FRAP analysis was carried out to determine the 
impact of these mutations on the rate of eIF2 
shuttling. One-phase association curves 
representing the recovery of eIF2 within eIF2B 
foci are shown in Figure 8A while representative 
images from the various stages of FRAP are 
displayed in Supp Figure 5E. In the presence of 
the K111E mutation, mobile eIF2 increased by 
12% (Figure 8B) and the T1/2 recovery of eIF2 
increased by 2.9 seconds, consistent with a 
decreased rate of recovery (Figure 8C). Similarly, 
in the presence of the Y274C mutation, mobile 
eIF2 increased by 24.6% (Figure 8B) and the T1/2 
recovery of eIF2 increased by 5.2 seconds, again 
consistent with a decreased rate of recovery 
(Figure 8D).  
 
These results highlight that while VWM 
mutations may have a similar impact on the 
activity of eIF2B, they show contrasting effects 
on eIF2B localisation. Currently, VWM 
pathophysiology is poorly understood largely due 
to limited correlation between the activity of 
mutant eIF2B and the severity of disease (33). 
These data highlight that VWM causing 
mutations impact upon eIF2B localisation which 




In this study, we explored the significance of 
eIF2B body formation in terms of GEF activity 
and eIF2B regulation. Since the initial 
identification of eIF2B bodies, several 
publications have attempted to elucidate the 
driving factors behind the localisation of eIF2B 
(24-31). While these studies have highlighted 
many interesting observations, they have resulted 
in confounding conclusions. The conflicting 
reports raise the question of whether eIF2B 
bodies form under steady-state growth or just 
under nutrient limiting conditions. We therefore 
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considered whether the differences in the 
methodologies used to visualise eIF2B could be 
responsible for the observed differences in eIF2B 
body formation. The conflicting studies were 
carried out in different yeast strains. Several 
differences have been identified across these 
yeast strains particularly in their stress response 
phenotypes and also within genes that controlling 
ribosome biosynthesis (44-46). Distinct 
ribosomal subpopulations that differ in their 
protein or RNA components are known to 
differentially control translation and its 
regulation within the cell (47). We therefore 
hypothesised that strain differences may impact 
the formation of eIF2B bodies.  In agreement with 
this, we found variation in the number of cells 
displaying eIF2B bodies across three different 
wild-type strains; with two strains harbouring 
eIF2B bodies in approximately 50 % of cells and 
the third strain presenting with a significantly 
lower percentage of cells harbouring eIF2B 
bodies (Figure 1B).  
 
Another consideration for differences observed in 
eIF2B localisation is whether the tag used to 
visualise eIF2B could be impacting on its 
localisation. Here we used a yeast enhanced GFP 
tag to visualise eIF2B localisation, GFP has a 
tendency to self-aggregate and therefore we 
wanted to ensure the eIF2B bodies we observed 
were not due to GFP aggregation. We 
individually tagged each of the 5 subunits of 
eIF2B and calculated the percentage of cells that 
contained eIF2B bodies. If the GFP tag was 
responsible for the aggregation of eIF2B into 
eIF2B bodies we would expect to see the same 
percentage of cells with eIF2B bodies, regardless 
of the eIF2B subunit tagged. These experiments 
revealed that localisation was not uniform across 
all subunits, suggesting that the eIF2B bodies we 
have observed are not due to aggregation of the 
GFP tag (Figure 1A). This is further supported by 
our previous work where eIF2B bodies were 
observed using CFP and YFP tags (24) and via 
immunolocalisation studies using both 
endogenous and HA-tagged subunits of eIF2B. 
(24, 25).  
 
Interestingly, cells with GFP tagged eIF2Bα or δ 
showed a reduced percentage of cells containing 
eIF2B bodies, compared to the other three eIF2B 
subunits. This decrease could be due to the 
position of the tag. The C-terminus of δ is 
important for heterodimerisation with eIF2Bβ 
whilst the C-terminus of eIF2Bα is important for 
homodimerization (48, 49). Analysis of recent 
eIF2B structures reveals that the interface 
between eIF2Bα and δ is largely formed from the 
C-terminus of both subunits (10-13) and 
analytical centrifugation experiments have 
demonstrated that eIF2Bα is required to stabilise 
the eIF2B decamer, with eIF2B(βδγε) tetramers 
unable to dimerise in the absence of eIF2Bα 
homodimers (15). Therefore, it is likely that the 
addition of the GFP protein tag to the C-terminus 
of either eIF2Bα or ẟ subunits would disrupt 
eIF2B decameric assembly. The decreased 
percentage of cells harbouring eIF2B bodies 
suggests that eIF2B decameric assembly may 
promote the formation of eIF2B bodies. In fitting 
with this hypothesis, we previously highlighted 
that the localisation of eIF2B bodies was 
dispersed in the presence of point mutations in 
eIF2Bα (26). Here, we have expanded on this and 
observed that deletion of the α subunit also leads 
to the complete dispersal of the eIF2B body 
(Figure 2A). It is therefore likely that the eIF2B 
decamer must form before eIF2B is able to 
localise and multimerise to give eIF2B bodies, 
illustrated in our model of eIF2B body formation 
presented in Figure 9.  
 
Although eIF2Bα is the only non-essential 
subunit of eIF2B in yeast, it does play critical 
roles in the regulation of translation initiation in 
response to stress (43). The dispersal of eIF2B 
bodies in the absence of eIF2Bα (Gcn3p) 
therefore suggests that the localisation of eIF2B 
may have a regulatory role in translation as a 
response to cellular stress. This interpretation is 
consistent with previous work studying the 
regulation of eIF2B localisation as a response to 
fusel alcohol stress where a decreased movement 
of eIF2B bodies within the cell was found to 
correlate with decreased translation (32). 
Furthermore, recent studies have suggested that 
eIF2B bodies form during cellular stress (28,31). 
Although we observed different numbers of cells 
with eIF2B bodies in three different wildtype 
strains during steady state growth, we were able 
to address the hypothesis that increased eIF2B 
body formation occurs during stress by 
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monitoring localisation under acute glucose 
starvation and the classical eIF2B dependent 
stress, amino acid starvation (Figure 1B).  
Although we did not see an increase in the 
number of cells displaying eIF2B bodies in the 
absence of glucose, we did see an increase when 
cells were subjected to amino acid starvation, 
suggesting that eIF2B dependent stress can 
enhance the formation of eIF2B bodies.  
 
A number of eIF2Bα mutations that abolish its 
regulatory function, thus rendering the cell 
unable to respond to stress, have been well-
characterised and are known as Gcn- mutations. 
These Gcn- mutations produced a phenotype 
where eIF2B was mostly dispersed throughout 
the cytoplasm (Figure 4Ai). Interestingly, while 
these mutations did not impact on the expression 
level of eIF2Bα (Gcn3p), this phenotype mirrored 
the phenotype observed from S. cerevisiae 
lacking the α subunit (gcn3Δ), implying that Gcn- 
mutations may completely abolish the α subunit 
from the decameric holocomplex (Figure 9). In 
mammalian cells eIF2B has been shown to form 
subcomplexs with reduced GEF activity in the 
absence of eIF2Bα (8, 29). The formation of these 
eIF2B subcomplexes has not been investigated in 
yeast, however yeast expressing these Gcn- 
mutations are viable suggesting active complexes 
of eIF2B are present within the cells. 
Crystallographic studies of eIF2B from S. 
cerevisiae localises Gcn- mutations to the eIF2ɑ-
P interface as well as the eIF2Bα-β and the 
eIF2Bα-δ interfaces (Figure 3), suggesting that 
stable interactions between the regulatory 
subunits are required for localisation (Figure 4). 
This is consistent with recent analysis of the 
eIF2B cryo-EM structure which indicates eIF2B 
bodies are formed by polymerisation of intact 
eIF2B decamers (30). As the decameric 
conformation of eIF2B is required for eIF2B to 
recognise and interact with eIF2α-P (23), it is 
therefore plausible that eIF2B cannot sense stress 
in the presence of these Gcn- mutants as a result 
of disruption to eIF2B assembly.  Interestingly a 
series of de novo human eIF2B1 variants have 
recently been identified in patients presenting 
with neonatal diabetes (45).  Two of these novel 
eIF2B1 mutations are equivalent residues to the 
Gcn- residues analysed in this work and they all 
map to the surface region of eIF2B1 which 
interacts with phosphorylated eIF2α.  This may 
imply that eIF2B localisation may be an 
important feature of these regulatory mutations in 
this disease.  Therefore, the Gcn- mutant analysis 
suggests that the eIF2B bodies are important for 
regulation. 
 
We were also interested to investigate the 
importance of eIF2B bodies for eIF2B GEF 
activity itself.  Gcd- mutations, which decrease 
the catalytic activity of eIF2B, consistently 
produced a phenotype with multiple eIF2B foci, 
which we termed microfoci (Figure 4Aii). 
However, Gcd- mutants still respond to the 
phosphorylation of eIF2α suggesting that eIF2Bα 
is still present within eIF2B and hence, the 
decameric structure is intact when these 
mutations are present (Figure S2B and Figure 9). 
Indeed, most of the Gcd- Gcn3p mutations do not 
seem to directly impede interactions between 
eIF2Bα and eIF2Bβ/δ (Figure 3). Instead, they 
are likely to affect the structural integrity of 
eIF2Bα subunit but it is currently unclear how 
this would lead to reduced catalytic capacity of 
eIF2B. Interestingly, microfoci were previously 
observed when interactions between the very 
long fatty acids (VLFA) beta-keto-reductase 
Ifa38p and the catalytic subunits eIF2Bε/γ were 
abrogated (51). This suggests that other 
interactions are important for the complete 
localisation of eIF2B to eIF2B bodies as well as 
its GEF activity. One exception observed in these 
studies was the AA 303//305Δ Gcd- mutant, 
which did not significantly decrease the number 
of eIF2B bodies formed. Previous studies on this 
particular mutant highlighted that the loss of 3 
amino acids at the extreme C-terminal domain 
upregulated the overall expression of gcn3 10-
fold (40).  Gcn3p appears to be integral for the 
formation of eIF2B bodies.   If levels of Gcn3p 
are upregulated in 303//305Δ Gcd- mutant cells, 
this overexpression of Gcn3p could partially 
rescue eIF2B body formation, thus cells 
displaying eIF2B bodies were observed in 
addition to the classical Gcd- microfoci 
phenotype.    
 
eIF2Bα VWM mutations were found to have 
diverse impacts on impact eIF2B body formation 
(Figure 7B).  VWM missense mutations, F240V 
and N209Y, displayed Gcn- phenotypes, as 
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determined by polysomal analysis (Figure 7A). 
N209Y mutant cells displayed a similar dispersed 
eIF2B localisation phenotype to the Gcn- mutant 
strains. Biochemical analysis of this conserved 
mutant in human cells demonstrated the mutant 
eIF2B complex was less sensitive to inhibition by 
eIF2α-P (35), supporting a role for eIF2B bodies 
in the regulation of eIF2B activity. In the F240V 
mutant, this dispersed phenotype was not 
observed and instead eIF2B bodies formed, but in 
a reduced percentage of cells. Interestingly, eIF2 
was not found to localise to these eIF2B bodies 
suggesting they are functionally impaired, 
perhaps contributing to the cells Gcn- phenotype. 
For the other VWM mutants, a reporter analysis 
suggests that the there are no gross deficiencies in 
the eIF2B GEF activity (Figure S4B), however 
the V184D mutant harboured an increased 
percentage of cells with microfoci and  the eIF2B 
bodies present in K111E and Y274C mutant cells 
displayed a slower rate of eIF2 shuttling implying 
they have decreased GEF activity. 
 
These data provide key insights into the 
formation of eIF2B bodies and their importance 
for eIF2B GEF activity and regulation within the 
cell. Under normal growth conditions eIF2B 
bodies exist in a strain-dependent manner, 
however in the presence of cellular stresses that 
target eIF2B activity through the phosphorylation 
of eIF2α, an increase in the percentage of cells 
harbouring eIF2B bodies occurs independent of 
strain. These data highlight a regulatory role for 
eIF2B bodies during cellular stress. This is 
further highlighted by complete loss of eIF2B 
bodies in the presence of Gcn- mutations, which 
abrogate the cells ability to respond to stress 
induced eIF2αP. In addition to their regulatory 
role, the formation of eIF2B bodies appears to 
correlate with enhanced eIF2B catalytic activity. 
Gcd- mutations, which decrease eIF2B GEF 
activity, disrupt eIF2B body formation resulting 
in cells exhibiting multiple smaller eIF2B 
containing foci termed microfoci. The catalytic 
activity of these microfoci is reduced when 
compared to eIF2B bodies. VWM causative point 
mutations also disrupted patterns of eIF2B 
localisation, providing the first evidence that 
eIF2B localisation may be linked to VWM 
pathophysiology.  VWM disease has a wide 
clinical spectrum and correlations between 
genotype and phenotype remain elusive. In 
certain cases, patients suffering the most severe 
VWM phenotypes harbour eIF2B mutations that 
biochemical studies have shown to have no 
impact on eIF2B complex formation or eIF2B 
activity (34). These data suggest that eIF2B 
modulation and regulation within eIF2B bodies 
may be a key facet to understanding the 




Strains construction and growth conditions 
Yeast strain genotypes are displayed in Table I 
and are derived from the W3031A yeast 
background strain with the exception of ySC 
which is derived from BY4741 and yMK1180 
which is derived from s288c yeast backgrounds. 
All strains are auxotrophic for specific amino 
acids or nucleobases. The strains were typically 
grown in rich YPD media (1 % (w/v) Yeast 
extract, 2 % (w/v) Bacto Peptone and 2 % (w/v) 
glucose) or in minimal synthetic complete media 
(SCD; 0.17 % (w/v) Yeast nitrogen base without 
amino acids, 0.5 % (w/v) ammonium sulphate, 2 
% (w/v) glucose) at 30°C (52), supplemented 
with specific dropouts (Formedium) depending 
on the genotype of the strain. In liquid media, 
strains were incubated at 30°C with agitation 
while growth on solid media, YPD or SCD was 
supplemented with 2 % (w/v) agar. Nutrient 
starvation was performed by the removal of all 
amino acids for 30 min and carbon source 
starvation was performed by the removal of 
glucose for 10 min.   
   
Plasmids used in this study 
The plasmids used in this study are Table II. A 
number of plasmids, denoted pAV, were kindly 
gifted by Prof. G. Pavitt (The University of 
Manchester).   
 
Site directed mutagenesis  
Site directed mutagenesis was performed using 
the QuikChange II XL kit (Agilent) as instructed 
by the manufacturers.  Plasmid DNA was isolated 
from multiple independent transformants and 
plasmids were Sanger sequenced to confirm the 
desired mutation had been generated. 
 
Western blot analysis  
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Protein extracts were generated from yeast 
cultures grown to an OD600 of 0.6. All cells were 
lysed and protein samples were prepared, 
electrophoretically separated, and subjected to 
immunoblot analysis as described previously 
(24). Western blotting was carried out as 
previously described (24) using the following 
antibodies;  eIF2B /Gcn3p (a kind gift from Prof. 
G. Pavitt, The University of Manchester, UK) at 
1:500 dilution  and Pab1p (a kind gift from Prof. 
M. Ashe, The University of Manchester, UK) at 
1:5000 dilution. Primary antibodies were 
detected using Goat anti-rabbit IRDye 680RD 
P/N 925-68071 and Goat anti-mouse IRDye 
800CW P/N 925-32210 (Licor) respectively.  
 
 
Assays of GCN4-lacZ Reporter Expression 
Standard methods for measuring the β-
galactosidase activity for strains bearing GCN4-
lacZ fusions were used (53). β-Galactosidase 
levels are expressed as nanomoles of o-
nitrophenol β-D-galactopyranoside hydrolyzed 
per min/μg of total protein. 
 
Live-cell imaging and quantification of eIF2B 
localisation 
Strains were grown at 30 °C until they reached an 
OD600 of 0.6. Cultures were placed on a 1 % (w/v) 
poly-L-lysine coated slide (ThermoFisher, UK) 
and visualised on a Zeiss LSM 510 confocal 
microscope using a 63 x plan-apochromat oil 
objective lens. To image GFP, an argon laser (488 
nm) was typically used with a maximum output 
of 25 mW at 55 % laser capacity. Images were 
analysed either using Zeiss 2009 software or the 
National Institutes of Health (NIH) ImageJ 
software. For each strain/mutant analysed, the 
localisation of eIF2B was assessed for 100 cells 
per replicate (unless otherwise stated) and 3 
independent replicates were performed. Three 
different localisation patterns were observed for 
eIF2B. The localisation pattern was defined as an 
eIF2B body, in cells where one large, commonly 
filamentous, structure could be observed.  In cells 
where eIF2B localised to multiple smaller 
punctate foci, these foci were defined as eIF2B 
microfoci. In cells where no eIF2B foci were 
visible and instead fluorescence was evenly 
distributed across the cytoplasm, the localisation 
phenotype of eIF2B was referred to as dispersed.  
 
Fluorescent recovery after photobleaching 
(FRAP) 
FRAP was performed to measure the shuttling of 
eIF2α-GTP through eIF2B foci as previously 
described by (24). Cytoplasmic foci were imaged 
and bleached using the argon laser at full 
capacity. Following the pre-bleach and bleach 
steps, the recovery of eIF2B into the cytoplasmic 
was followed by taking iterative images every 1.8 
seconds for 25 cycles. 25 cells were analysed for 
each replicate. 
 
Fluorescence recovery was normalised to the 
total fluorescence of the cell. Background 
fluorescence was also measured and subtracted 
from fluorescence recovery. Normalised data was 
fitted to a one-phase association curve to find 
mobile eIF2 and half-time recovery. A rate of 
recovery was calculated from the one-phase 
association curves by dividing the plateau by the 
rate constant (k). The eIF2 content of cytoplasmic 
foci was determined using NIH ImageJ software. 
 
Analysis of ribosome distribution on sucrose 
gradients.  
Yeast cultures were grown to an OD600 of 0.6 and 
harvested by centrifugation.  When cells were 
subjected to nutritional stress (e.g. amino acid or 
glucose  starvation) cultures were split into two 
50 mL cultures, centrifuged and resuspended in 
media either with or without amino acids or 
glucose, as described above.  Cells  were lysed in 
polyribosomal buffer containing 100 µg/ml 
cycloheximide and 2.5 OD260 units of extracts 
were layered onto 15–50% sucrose gradients. 
sucrose gradients were poured as previously 
described (24). The gradients were sedimented 
via ultracentrifugation at 40,000 rpm using a Th-
641 swing-out rotor in a Sorvall WX 
Ultracentrifuge or 2.5 h. Monosome and 
polysome peaks were quantified using the 






To determine statistical significance between 
different groups within each data set, a Shapiro-
Wilk test was performed to test for normality. All 
data presented was considered non-parametric 
and therefore, individual groups were compared 
to each other using the Kruskal-Wallis test 
followed by a Conover Inman posthoc test. 
 
Structural analysis of eIF2Bα mutations 
PyMOL was used to produce eIF2B structural 
representations using crystal structure data 
derived from S.cerevisiae, PDB ID: 6i3m and 
6i7t (10). The structure of the eIF2B complex is 
shown in ribbon representation with individual 
subunits coloured and labelled. The eIF2Bα 
homodimer is shown in surface representation 
with residues residing within the interface 
between the eIF2Bα subunits and either eIF2B 
subunits or the alpha subunit of eIF2 are colour 
coded. eIF2Bα mutant residues were identified 
and labelled with proximal residues from other 
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Table I. Yeast strains used within this study 
Strain  Genotype Source 
yMK880 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418 
(24) 
yMK883 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180, SUI2-yeGFP::G418 
(24) 
yMK1402 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2 
(25) 
ySC37 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3 URA3  2μ] 
This study 
ySC38 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-T41A URA3  
2μ] 
This study 
ySC39 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-E44V URA3  
2μ] 
This study 
ySC40 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-E44K URA3  
2μ] 
This study 
ySC41 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-F73L URA3  
2μ] 
This study 
ySC42 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-N80D URA3  
2μ] 
This study 
ySC43 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-F240I URA3  
2μ] 
This study 
ySC44 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-T291P URA3  
2μ] 
This study 
ySC45 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-S293P URA3  
2μ] 
This study 
ySC46 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3 URA3  CEN] 
This study 
ySC47 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-A25V, A26V 
URA3  CEN] 
This study 
ySC48 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 





ySC49 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-R104K URA3  
CEN] 
This study 
ySC50 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-V295F URA3  
CEN] 
This study 
ySC51 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-D71N URA3  
CEN] 
This study 
ySC52 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-E199K URA3  
CEN] 
This study 
ySC53 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-AA303-305Δ 
URA3  CEN] 
This study 
ySC54 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3 URA3  
CEN4ARS6] 
This study 
ySC55 Matα, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-K111E URA3  
CEN4ARS6] 
This study 
ySC56 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-V184D URA3  
CEN4ARS6] 
This study 
ySC57 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-N209Y URA3  
CEN4ARS6] 
This study 
ySC58 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-F240V URA3  
CEN4ARS6] 
This study 
ySC59 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-Y274C URA3  
CEN4ARS6] 
This study 
ySC16 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 




Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180, SUI2-GFP::G418, gcn3::LEU2, p[GCN3 URA3  
CEN] 
This study 
ySC62 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180, SUI2-GFP::G418, gcn3::LEU2, p[GCN3-
A25V,A26V URA3  CEN] 
This study 
ySC67 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180, SUI2-GFP::G418, gcn3::LEU2, p[GCN3-E199K 
URA3  CEN] 
This study 
ySC68 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180, SUI2-GFP::G418, gcn3::LEU2, p[GCN3-AA303-




ySC9 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 GCD1-yeGFP::HygR This study 
yMK1180 MATα leu2-3, 112, ura3-52::[HIS4-lacZ ura3-52] ino1, gcd6Δ,  
gcn2Δ::hisG, GCD1-yeGFP::G418, p[GCD6 CEN6 LEU2] 
 
ySC91 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 
p[GCN3 URA3 CEN6ARS4] 
This study 
ySC92 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 
p[gcn3 K111E URA3 CEN6ARS4] 
This study 
ySC93 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 
p[gcn3 V184D URA3 CEN6ARS4] 
This study 
ySC94 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 
p[gcn3 N209Y URA3 CEN6ARS4] 
This study 
ySC95 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 
p[gcn3 F240V URA3 CEN6ARS4] 
This study 
ySC96 Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 
p[gcn3 Y274C URA3 CEN6ARS4] 
This study 
 
Table II. Plasmids used within this study 
Name 
Name Genotype Source 
pSC116 p[GCN3 K111E URA3 CEN6ARS4] This study 
pSC117 p[GCN3 V184D URA3 CEN6ARS4] This study 
pSC118 p[GCN3 F240V URA3 CEN6ARS4] This study 
pSC119 p[GCN3 Y274C URA3 CEN6ARS4] This study 
pAV1108 p[GCN3(T41A) URA3 2μ] (40) 
pAV1109 p[GCN3(E44V)URA3 2μ] (40) 
pAV1110 p[GCN3(E44K)URA3 2μ] (40) 
pAV1111 p[GCN3(F73L) URA3 2μ] (40) 
pAV1112 p[GCN3(N80D) URA3 2μ] (40) 
pAV1113 p[GCN3(F240I) URA3 2μ] (40) 
pAV1115 pGCN3 (T291P) URA3 2μ] (40) 
pAV1116 p[GCN3 (S293R) URA3 2μ] (40) 
pAV1117 p[GCN3 URA3 2μ] (40) 
20 
 
pAV1170 p[GCN3 URA3 CEN] (40) 
pAV1239 p[GCN3(AA2526VV) URA3 CEN] (40) 
pAV1240 p[GCN3(A26T) URA3 CEN] (40) 
pAV1241 p[GCN3(R104K) URA3 CEN] (40) 
pAV1242 p[GCN3(V295F) URA3 CEN] (40) 
pAV1243 p[GCN3(D71N) URA3 CEN] (40) 
pAV1244 p[GCN3(E199K) URA3 CEN] (40) 
pAV1268 p[GCN3(303//305Δ) URA3 CEN] (40) 
pAV1729 p[GCN4 leader-lacZ-TRP1] (40) 
pAV1769 p[GCN3 URA3 CEN6 ARS4] (43) 
pAV1778 p[GCN3(N209Y) URA3 CEN6 ARS4] (43) 
 
Figure 1 – The percentage of cells containing eIF2B bodies differs depending on the subunit
C-terminally tagged and the lab strain of S. cerevisiae. (A) Each eIF2B subunit was
individually C-terminally GFP-tagged in the W303-1A background strain. The number of cells
displaying eIF2B bodies was analysed and presented as a percentage of total cells counted, a
minimum of 50 cells were counted for each experiment, n=3. (B) GCD1 (eIF2Bγ) was C-
terminally GFP-tagged in the S. cerevisiae background strains W303-1A (yMK880), BY4741
(ySC9) and S288c (yMK1180). Following logarithmic growth, each strain was subjected to
amino acid and glucose starvation for 30 minutes, before eIF2B localisation was assessed. The
number of cells displaying eIF2B bodies was analysed and presented as a % of total cells






























Figure 2 – eIF2Bα is required for eIF2B body formation. (A) Confocal microscopy of GCD1-
yeGFP (yMK880), SUI2-yeGFP (yMK883), GCD1-yeGFP gcn3::LEU2 (yMK1402) and SUI2-
yeGFP gcn3::LEU2 (ySC16). Null strains were transformed with a low copy Cen plasmid
(pAV1170) or a high copy 2μ plasmid (pAV1117) containing WT GCN3. (B) A minimum of 100
cells were counted and assessed as to whether eIF2B bodies were present, dispersed or localised
to microfoci. Overnight cultures were diluted in SCD media to 0.2 OD600 and incubated at 30°C
with shaking until exponential growth was reached. n=3. Error bars are representative of SD, ns =
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Figure 3 – Structural schematic highlighting eIF2Bα mutations. A) The crystal structure solved for S. cerevisiae eIF2B is
shown in ribbon representation. B) The eIF2B homodimer has been enlarged and is shown as a surface representation with
interfaces between eIF2Bα and the other eIF2B/eIF2 subunits colour coded. The position of the amino acid mutations
introduced in this study are highlighted. These mutants where modelled on the crystal structure data and are stick
representations are shown with amino acids from neighbouring eIF2B/eIF2 subunits highlighted. Gcn- mutants are shown in
purple and Gcd- mutants in turquoise. These mutations were expressed in the yMK1402 background strain. (Gcn- mutants




















Gcn- mutants mapped onto eIF2Bα homodimer












































Figure 4 – eIF2Bɑ mutants alter the localisation of eIF2B bodies (A) Cells were grown to log phase and
confocal microscopy was used to image the strain yMK1402 (GCD1-yeGFP gcn3::LEU2) containing a series of
(i) Gcn-mutants [pAV1108–13, 15 and 16] and (ii) Gcd- mutants [pAV1238-44 and 68]. (B) Cells from each
strain were counted to assess whether eIF2B bodies were present, dispersed or localised to microfoci The first part
of the graph corresponds to the gcn- mutants and the second part shows the gcd- mutants For each strain analysed
the localisation of eIF2B was assessed for 100 cells per biological replicate, n=3. Error bars are representative of






Figure 5 – FRAP analysis of gcn3 Gcd- mutations reveal slower shuttling of eIF2 through eIF2B microfoci. A) Schematic
representation of FRAP technique. The eIF2B body/microbody is bleached and the intensity of fluorescent signal within this
region is measured, normalised against intensity of the pre-bleached signal and plotted against time. Mobile eIF2 is calculated
as the plateau of the FRAP curve. t1/2 Recovery is calculated as the fluorescence measured at the halftime point of total
recovery. The rate or recovery is calculated by dividing the plateau value by the rate constant (k). B) Three gcn3 Gcd-
mutations AA25,26VV (pAV1239), E199K (pAV1244) and 303//305Δ (pAV1268)) as well as the GCN3 Cen plasmid
(pAV1170) were exogenously expressed in SUI2-yeGFP gcn3::LEU2 (ySC16) to measure eIF2 recovery within eIF2B bodies.
Both eIF2B body and microfoci were analysed for the 303//305Δ mutant. (B) Normalised FRAP recovery curves Gcd-
mutations AA25,26VV (pAV1239), E199K (pAV1244) and 303//305Δ (pAV1268)) as well as the GCN3 Cen plasmid
(pAV1170) were exogenously expressed in SUI2-yeGFP gcn3::LEU2 (ySC16) C) (i) Bar chart representing the mobile eIF2
within the foci as a percentage. (ii) Bar chart representative of half the time needed for eIF2 to fully recover. (iii) Bar chart
depicting the rate of eIF2 recovery. Data are representative of 25 cells, n=3, error bars are representative of SD, ns = not
significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001.




DNA Protein Disease Severity Zygosity
Yeast 
Conservation Reference
c.328A>G p.Lys110Glu Classical Homozygous p.Lys111 Zhang et al., (2015)
c.574G>T p.Val183Phe Juvenile / Adult Homozygous p.Val184
Ohlenbusch et 
al., (2005)
c.622A>T p.Asn208>Tyr N/R Heterozygous with IVS2+1G>A p.Asn209
Van der Knaap 
et al., (2002)
c.715T>G p.Phe239Val Juvenile / Adult Homozygous p.Phe240
Shimada et al., 
(2015)
c.824A>G p.Tyr275Cys N/R Heterozygous with Gly204Δ p.Tyr274
Maletkovic et al., 
(2008)
N/R: Not reported. IVS: Intervening sequence.
Figure 6 – Structural schematic highlighting eIF2Bα VWM mutations. A) The crystal structure
solved for S. cerevisiae eIF2B is shown on the left in surface representation. B) On the right the eIF2B
homodimer has been enlarged and is shown as a surface representation with interfaces between eIF2Bα
and the other eIF2B subunits colour coded. The position of the amino acid mutations introduced in this
study are highlighted. These mutants where modelled on the crystal structure data and are shown in
orange as stick representations, with amino acids from neighbouring eIF2B subunits highlighted. C)
The VWM disease severity, zygosity and yeast conservation of these mutations is outlined. These
mutations were expressed in the ySC16 background strain. (PDB ID: 6i7t)
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Figure 7 – eIF2B localisation in the presence of gcn3 containing VWM missense mutations. (A)
Polysome analysis of the strain yMK1402 (GCD1-yeGFP gcn3::LEU2) expressing gcn3 VWM
mutants and the low copy WT GCN3 plasmid (ySC91-96. Polysome analysis was as described in
Materials and Methods. Polysome/ monosome ratios were calculated from measuring the area under
the polysome peaks and dividing by the monosome peak area. (B) (i) Cells were grown to log phase
and confocal microscopy was used to image the strain yMK1402 (GCD1-yeGFP gcn3::LEU2)
expressing gcn3 VWM mutants, Gcn3pK11E (p[GCN3 K111E URA3 CEN6ARS4]), Gcn3pV184D
(p[GCN3 V184D URA3 CEN6ARS4]), Gcn3pN209Y (p[GCN3 N209Y URA3 CEN6ARS4]),
Gcn3pF230V (p[GCN3 F240V URA3 CEN6ARS4]), Gcn3pY274C (p[GCN3 Y274C URA3 CEN6ARS4])
and the low copy WT plasmid p[GCN3 URA3 CEN6 ARS4]. (ii) Cells from each strain were counted
to assess whether eIF2B bodies were present, dispersed or localised to microfoci For each strain
analysed the localisation of eIF2B was assessed for 100 cells per replicate, n=3. Error bars are
representative of SD. Ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001.
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Figure 8 – FRAP analysis of eIF2 cycling through eIF2B foci in the presence of VWM gcn3
mutations reveal an increase in eIF2 recovery at a slower rate. i) Normalised FRAP recovery
curves for the strain ySC16 (SUI2-yeGFP gcn3::LEU2) expressing the VWM mutants Gcn3pK11E
(p[GCN3 K111E URA3 CEN6ARS4]), Gcn3pY274C (p[GCN3 Y274C URA3 CEN6ARS4]) and the
low copy WT plasmid p[GCN3 URA3 CEN6 ARS4] (ii) Bar chart representing the percentage
mobile eIF2 within the foci for each mutant. (iii) Bar chart representing the T1/2 needed for eIF2
to fully recover. (iv) Bar chart depicting the rate of eIF2 recovery. Data are representative of 25
cells per replicate, n=3, error bars are representative of SD, ns = not significant, * P=<0.05, **
P=<0.01, *** P=<0.001, **** P=<0.0001.
Figure 9 - Schematic of the relationship between the localisation phenotype of eIF2B
and its structure, activity and regulation. In yeast eIF2B displays 3 distinct localisation
phenotypes: dispersed eIF2B, eIF2B bodies or eIF2B microfoci. In its active, decameric form,
eIF2B localises to eIF2B bodies. In the absence of eIF2Bα, this localisation is lost and a dispersed
eIF2B localisation phenotype is observed. eIF2B cannot for an octameric complex in the absence of
eIF2Bα and thus we hypothesise eIF2B tetrameric and heterodimeric subcomplexs form. The
dispersed eIF2B phenotype is mimicked by Gcn- mutants suggesting a regulatory role for the eIF2B
body. Additionally, the localisation of eIF2B to eIF2B bodies appears to enhance eIF2B GEF. Gcd-
mutants which decarease GEF activity disrupt eIF2B body localisation and result in an eIF2B
microfoci localisation phenotype. The eIF2B microfoci have a decreased interaction with eIF2 and
thus appear to have decreased eIF2B GEF activity.
